1.3 In 2014, U.S.-based Horizon Pharma purchased a smaller, Irish-based company, Vidara Therapeutics International. In 2015, the combined company had before-tax profit of approximately $40,000,000. In 2015 the U.S. corporate income tax rate was about 35 percent; the Irish corporate income tax rate was about 22 percent. If you are the CEO of Horizon Pharma, what strategy would you have pursued in making the merger, and why?